Effects of Resistant Starch Diet on the Gut Microbiome in Chronic Kidney Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03356990|
Recruitment Status : Recruiting
First Posted : November 29, 2017
Last Update Posted : April 2, 2021
|Condition or disease||Intervention/treatment||Phase|
|Chronic Kidney Diseases||Dietary Supplement: Resistant Starch||Not Applicable|
Chronic kidney disease (CKD), a progressive decline in kidney function, is a growing health problem: 13% of adults in the US have CKD. Among patients with CKD, the risk of progression to irreversible loss of kidney function (end-stage renal disease, ESRD) is about 1% per year. In addition, adjusted mortality is approximately four times greater among those with CKD compared to those without. For ESRD, apart from dialysis and kidney transplant, no treatment exists. CKD increases urea levels in bodily fluids leading to a dominance of urease-containing bacteria in the gut. Such dysbiosis results in decreased production of the short chain fatty acid, butyrate and decreased health of the colonic epithelial barrier. Consequently, bacterial toxins translocate into the bloodstream, promoting inflammation. Moreover, production of uremic toxins such as indoxyl and p-cresyl sulfates are also increased, resulting in further kidney injury.
CKD patients are prescribed a diet low in protein, fiber and symbiotic organisms, which reduces complications like hyperkalemia, but also contributes to the dysbiosis. Re-formulating the CKD diet may improve the clinical management of CKD. The investigators's overall hypothesis is that changes in the microbial diversity, xeno-proteins and xeno-metabolites correlate with CKD progression, and microbiome-directed therapies can be used to slow the disease. In this study, the investigators will determine the tolerability of supplemental resistant starch (RS). Secondary aims are to determine if a diet high in resistant starch changes fecal butyrate concentrations, the make-up of the gut microbiome and the concentrations in the blood of uremic toxins produced by the gut microbiome. This study will help in the design of a future study with the aim of understanding if a high resistant starch diet can slow the progression of chronic kidney disease.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Resistant Starch Diet on the Gut Microbiome in Chronic Kidney Disease|
|Actual Study Start Date :||February 12, 2018|
|Estimated Primary Completion Date :||September 1, 2021|
|Estimated Study Completion Date :||December 1, 2021|
Experimental: Resistant Starch
Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose of Hi-Maze 260 or "High RS Gummy Chews" in the morning and the other half dose in the evening
Adult participants are asked to introduce in their diet 30 grams of high RS supplement each day of the diet period (2 weeks).
Children of age included between 5 and 9 years are asked to introduce in their diet 10 grams of high RS supplement each day of the diet period (2 weeks).
Children of age included between 10 and 17 years are asked to introduce in their diet 15 grams of high RS supplement each day of the diet period (2 weeks).
Dietary Supplement: Resistant Starch
Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or "High RS Gummy Chews" in the morning and the other half dose (one bag) in the evening.
- Percentage of subjects that consume at least 90% of the dietary resistant starch (RS). [ Time Frame: 2 weeks ]Packaging will be returned by the subject at the end of the time period in order to determine compliance.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03356990
|Contact: Tawana L Gibbs, MA,MET||501-68-65301||Tgibbs2@uams.edu|
|United States, Arkansas|
|University of Arkansas for Medical Sciences||Recruiting|
|Little Rock, Arkansas, United States, 72205|
|Contact: John M Arthur, MD. Ph.D. 501-686-5295 JMArthur@uams.edu|
|Contact: Tawana L Gibbs, MET 501-686-5301 GDusio@uams.edu|
|Sub-Investigator: Boris Zybaylov, Ph. D.|
|Sub-Investigator: Mohammad Ilyas, MD|
|Sub-Investigator: Manisha Singh, MD|
|Sub-Investigator: Gerren Hobby, MD|
|Principal Investigator:||John M Arthur, MD, Ph.D.||University of Arkansas|